All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your MDS Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Is there synergy between anti-TIM-3 therapy and HMAs in the treatment of MDS?
Bookmark this article
During the 25th Congress of the European Hematology Association (EHA), the MDS Hub spoke to Uma Borate, OHSU Knight Cancer Institute, Portland, US. We asked: Is there synergy between anti-TIM-3 and hypomethylating therapy in the treatment of MDS?
Is there synergy between anti-TIM-3 therapy and HMAs in the treatment of MDS?
TIM-3 is a co-inhibitory receptor involved in regulating both innate and adaptive immunity. TIM-3 is expressed on leukemic stem cells and blasts, but is not present on healthy hematopoietic stem cells, making it an attractive target to enhance immune-mediated tumor destruction. Preclinical studies on models of acute myeloid leukemia and MDS have highlighted synergistic activity of anti-TIM-3-targeted antibody therapy and hypomethylating agents.
Uma Borate outlines the progression of this combination into clinical studies.
Related articles
Newsletter
Subscribe to get the best content related to MDS delivered to your inbox